Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Immunotherapy Logo (drop shadow)

PART OF NEXTGEN BIOMED 2026

24 - 25 March 2026 | QEII Centre, London, UK

Programme Summary

A carefully curated event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of novel immunotherapies; advances in cellular, antibody and combination therapy development as well as personalised cancer therapy treatments.

Hear from past attendees of the NextGen Biomed 2025 conference

DAY TWO

Immunotherapy & Immuno-oncology Keynote Address

SIR MARC FELDMANN AC, FRS, Emeritus Professor, University of Oxford

Sir Marc Feldmann is a pioneering immunologist whose groundbreaking discovery that
blocking TNF-a could stop the destructive inflammation of rheumatoid arthritis laid
the foundation for modern immunotherapy.

His work directly led to the development of anti-TNF drugs, now life-changing treatments for millions of patients with autoimmune diseases worldwide. Widely recognized as one of the founders of immunotherapy, he has been honoured with the Lasker Award, Crafoord Prize, Tang Prize, and a knighthood for his transformative contributions to medicine.

2026 Highlights

Unlock the future of immunotherapy - from early discovery of novel cancer and
autoimmune targets to next-generation cancer vaccines. Explore how cutting-edge
biomarker and omics technologies are transforming translational insights into advanced
cell & gene therapies, predictive models, and precision medicine breakthroughs.

Unlock the future of precision immuno-oncology with cutting-edge biomarker
strategies—driving smarter combinations, sharper patient selection, and breakthrough
technologies that predict response and power truly personalised immunotherapy.

Explore the next wave of autoimmune disease therapies, from tolerisation
strategies to TCR and T cell–based approaches. Discover how advances in mRNA,
dendritic cell immunotherapy, and targeted antibody therapies are reprogramming the
immune system to deliver precise, lasting treatments for patients

NextGen Biomed - What to Expect Poster 2
NextGen Biomed - What to Expect Exhibiting 2
NextGen Biomed - What to Expect Networking 5
1000

leading pharma, biotech, regulatory & academic delegates

700
pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments
NGB + LSX Combined Logo-1

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things NextGen Biomed, direct to your inbox.

NGB Newsletter Icon-1

Immunotherapy & Immuno-oncology Agenda at a Glance

EVENT KICK OFF DAY - 23 MARCH

Track 4: Cancer Vaccines & Personalised Cancer Therapies 

DAY ONE - 24 MARCH

Track 8: Discovery & Development Of Therapies For Cancer & Autoimmune Diseases 
Track 9: Biomarker-Driven Personalised Immunotherapy 
Track 10: Next-Generation Targets & Emerging Therapeutic Platforms 

DAY TWO - 25 MARCH

Track 8: Enhancing Clinical Outcomes: Imaging, Modelling, Liquid Biopsy & Combination Strategies  
Track 9: Multi-Omics & Spatial Technologies in Immuno-Oncology
Track 10: Translational Models in Immuno-Oncology: In Vitro & In Vivo Approaches

NextGen Biomed Conference Brochure

Meet Our Expert Speakers

Immunotherapy & Immuno-oncology again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Annelise Vuidepot, PhD
Senior Vice President & Chief Technical Officer - Head of Pipeline & Platform Research and UK site Head,
Immunocore
Lilly Wollman
Chief Executive Officer,
Synteny
Marc Feldmann AC, FRS
Emeritus Professor,
University of Oxford
Simon Plyte
Chief Scientific Officer,
Biomunex Pharmaceuticals
Show More Speakers
Hide Speakers
Alex Frankell
Group Leader,
University of Cambridge
Alexander Eggermont
Professor, Clinical & Translational Immunotherapy,
Prinses Máxima Centrum Paediatric Oncology
Ali Roghanian
Associate Professor in Cancer Immunology/Immunotherapy,
University of Southampton
Allan Bradley
Founder, Director and Chief Scientific Officer,
T-Therapeutics
Brenda Iglesias
Associate Director, Strategic Partnerships,
GSK
Callum Scott
Head of Development,
Scancell Ltd
Christian Mueller
Chief Development Officer,
Immutep
Christian Garde
Director, Bioinformatics,
Evaxion AI
Colette Johnston
VP Product Pipeline,
Enara Bio
Darren Hodgson
Executive Director Cancer Biomarker Development,
AstraZeneca
Elaine Dymond
Vice President, Global Quality,
Autolus
Gabriel Wong
Senior Medical Director,
AstraZeneca
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Henoch Hong
Associate Director,
Merck Healthcare KGaA
James Legg
Chief Scientific Officer,
Cytospire Therapeutics
Jennifer Mataraza
Executive Director and Head, Translational Immuno-Oncology,
Novartis Institutes For Biomedical Research
John Bridgeman
Chief Scientific Officer,
Immunokey
Kamaraj Karunanithi
Director of Research and Innovation,
University Hospitals of North Midlands NHS Trust
Larisa Soldatova
Professor & Reader in Data Science,
University of London
Livija Deban
Chief Scientific Officer,
Prokarium
Mariolina Salio
Director Experimental Immunology,
Immunocore
Markus Templin
Head - Cellular & Molecular Biology,
NMI
Miguel Gaspar
Senior Director,
Astrazeneca
Mihaela Bozic
Scientist,
T-Therapeutics Ltd
Ni Huang
Associate Director,
T-Therapeutics Ltd
Panagiota Spantidea
Senior Scientist, In Vivo Pharmacology & Toxicology,
Byondis B.V.
Ricardo Carreira
Associate Director,
Immunocore
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Thakshila Liyanage
Founder/CEO,
Early is Good
Vaios Karanikas
Biomarker Portfolio Leader,
Roche
Vicky Brentville
Principle Scientist,
Scancell
Xi Zhao
Head, Oncology Bioinformatics, Research & Development,
AbbVie
Yi-Ru Yu
Lead Scientist,
Pilatus Biosciences SA

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Register Now

Be part of the new wave of Biomed R&D innovation

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients